Clinical trial NCT01950273: Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
Official title: A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lymphoma, Follicular
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2013-09-25
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to assess the pharmacokinetic (PK) similarity of Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients with low tumor burden follicular lymphoma (LTBFL).

The secondary objective of the study is to evaluate the pharmacodynamics (PD), safety, and anti-tumor activity of BI 695500 vs. rituximab (MabThera®), as well as the presence of anti-drug antibodies (ADAs).


Eligibility criteria: Inclusion criteria:

* Must give written informed consent and be willing to follow this Clinical Trial Protocol.
* Male or female patients, at least 18 years of age at Screening.
* Histologically-confirmed, stage II - IV Non-Hodgkin's lymphoma (CD20+ FL of Grades 1, 2, or 3a).
* Low tumor burden according to the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria - no nodal or extranodal involvement of more than 7 cm, no more than 3 nodal sites with a diameter \>3 cm, no B symptoms (i.e., fever \>38°C, weight loss - unexplained loss of \>10 % body weight over the past 6 months, and sweats - the presence of drenching night sweats), no significant splenomegaly, no significant serious effusion, no complications such as organ compression, and less than 5x10\^9/L circulating tumor cells.
* Availability of archived tumor sample prior to screening.
* Patients not previously treated for their FL.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
* Have at least 1 measurable lesion as per the International Working Group (IWG) criteria 2007 at Screening (lesion clearly measurable in at least 2 perpendicular dimensions; see Appendix 10.1 for further details).
* Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) within 28 days prior to randomization, including:
* - hemoglobin =9.0 g/dL (=5.6 mmol/L).
* - absolute neutrophil count =1.5 × 10\^9/L.
* - platelet count =100 × 10\^9/L.
* Adequate renal and liver function:
* - serum creatinine \<2.0 mg/dL (\<176.8 micromol/L).
* - total bilirubin \<2.0 mg/dL (\<34 mcmol/L) except for patient with Gilbert's Syndrome or Hemolysis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3 x upper limit of normal (ULN) (\<5 x ULN is acceptable if abnormalities are thought to be related to hepatic infiltration by FL).
* For participants of reproductive potential (males and females), use of a medically acceptable method of contraception during the trial, i.e., a combination of 2 forms of effective contraception (defined as hormonal contraception, intrauterine device, condom with spermicide, etc.). Females of childbearing potential (includes tubal ligation) and males with female partners of childbearing potential must also agree to use an acceptable method of contraception (see above) for 12 months following completion or discontinuation from the trial medication.

Exclusion criteria:

* Transformation to high-grade lymphoma (secondary to low-grade lymphoma).
* Presence or history of central nervous system lymphoma.
* Patients receiving current treatment with corticosteroids must not be receiving a dose exceeding 20 mg/day prednisone or equivalent.
* Patients with prior or concomitant malignancies within 5 years prior to screening except non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, adequately treated breast cancer in situ, localized prostate cancer stage T1c - provided that the patient underwent curative treatment, and remains relapse free.
* Major surgery (excluding lymph node biopsy) within 28 days prior to randomization.
* Active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., Human Immunodeficiency Virus \[HIV\], Hepatitis C Virus \[HCV\], Herpes Zoster); positive for HIV or tuberculosis at Screening.
* Patients with serological evidence of Hepatitis B virus (HBV) infection. Patients seropositive because of HBV vaccine are eligible. HBV positive patients may participate following consultation with a hepatitis expert regarding monitoring and use of HBV antiviral therapy, and provided they agree to receive treatment as indicated.
* Serious underlying medical conditions, which, per the investigator's discretion, could impair the ability of the patient to participate in the trial (including but not limited to ongoing active infection, severe immunosuppression, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease); patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the NYHA classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease.
* Known hypersensitivity or allergy to murine products.
* History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug.
* Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.
* Prior treatment with BI 695500 and/or rituximab.
* Patients who received any prior therapy using monoclonal antibodies will be excluded; this does not apply to other biological drugs such as growth factors or anticoagulants.
* Treatment within a clinical trial within 4 weeks prior to initiation of trial treatment. Patients who have received treatment with a drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, of the initial dose of trial medication.
* Any other co-existing medical or psychological condition(s) that will preclude participation in the trial or compromise ability to give informed consent and/or comply with study procedures.
* Pregnancy or breast feeding. For women of childbearing potential, a positive serum pregnancy test at the Screening Visit.
* Patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the New York Heart Association (NYHA) classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease; or uncontrolled hypertension.

Primary outcomes:
measure: Area Under the Concentration (AUC) Time Curve of BI 695500 and Rituximab (MabThera®) Over the First Dosing Interval (Pre-infusion on Day 1 to Pre-infusion on Day 8)
timeFrame: Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 1, and at 24, 48, 72, 96 and 168 hours from start of infusion 1.
Secondary outcomes:
measure: AUC of BI 695500 and Rituximab (MabThera®) Over the Fourth Dosing Interval (Pre-infusion on Day 22 to Day 29) (AUC Day 22-Day 29)
timeFrame: Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 4, and at 24, 48, 72, 96 and 168 hours from start of infusion 4.
measure: Maximum Measured Concentration of BI 695500 and Rituximab (MabThera®) in Plasma (Cmax) Following Dose 1
timeFrame: Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 1, and at 24, 48, 72, 96 and 168 hours from start of infusion 1.
measure: Maximum Measured Concentration of Rituximab (MabThera®) and BI 695500 in Plasma (Cmax) Following Dose 4
timeFrame: Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 4, and at 24, 48, 72, 96, 168, 336, 672, 1344, 2016 and 2880 hours from start of infusion 4.
measure: Area Under the Depletion-time Curve of the Cluster of Differentiation (CD)19+ B-cell Count (% Change From Baseline (CFB)) in Peripheral Blood From Pre-infusion on Day 1 Until Last Measurement on Day 8 (Pre-infusion)
timeFrame: Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion, and at 24, 48, 72, 96 and 168 hours from start of infusion.
measure: Change From Baseline (%) of CD19+ B-cells in Peripheral Blood Measured After Seven Days on Day 8 (Day 8 Pre-infusion Time Point)
timeFrame: Blood sampling was done at 168 hours from start of infusion.
measure: Overall Response Rate (ORR) (Complete Response (CR) Plus Partial Response (PR)) Evaluated Approximately One Month After Last Dose of BI 695500 or Rituximab (MabThera®)
timeFrame: at Day 50.
measure: Percentage of Patients With Treatment Emergent Adverse Events (TEAEs) Selected for Comparability Assessment of BI 695500 and Rituximab (MabThera®)
timeFrame: Adverse Events (AEs) that started or worsened on or after the first dose of study medication and prior to the last date of study medication + 4 months (120 days) inclusive.
Other outcomes:
Locations:
city: Canberra
country: Australia
facility: The Canberra Hospital
state: Migration Data
city: Wien
country: Austria
facility: AKH - Medical University of Vienna
city: Bruxelles
country: Belgium
facility: Brussels - UNIV St-Luc
city: Leuven
country: Belgium
facility: UZ Leuven
city: Namur
country: Belgium
facility: Namur - HOSP Ste-Elisabeth
city: Zagreb
country: Croatia
facility: Clinical Hospital Centre Zagreb
city: Brno
country: Czechia
facility: University Hospital Brno
city: Ostrava-Poruba
country: Czechia
facility: University Hospital Ostrava
city: Praha 2
country: Czechia
facility: Vseobecna fakultni nemocnice V Praze
city: Bordeaux cedex
country: France
facility: INS Bergonié
city: Brest
country: France
facility: HOP Morvan
city: La Roche sur Yon
country: France
facility: Centre Hospitalier Départemental Les Oudairies
city: Pessac
country: France
facility: HOP Haut-Lévêque
city: Poitiers
country: France
facility: Hôpital la Milétrie - CHU Poitiers
city: Bad Nauheim
country: Germany
facility: Gesundheitszentrum Wetterau gGmbH
city: Dresden
country: Germany
facility: Universitätsklinikum Carl Gustav Carus Dresden
city: Freiburg
country: Germany
facility: Universitätsklinikum Freiburg
city: Hamburg
country: Germany
facility: Haemato-Onkologie Hamburg
city: Kassel
country: Germany
facility: Klinikum Kassel GmbH
city: Athens
country: Greece
facility: General Hospital of Athens "G. Gennimatas"
city: Budapest
country: Hungary
facility: Semmelweis University, 1st Dept. Internal Medicine
city: Auckland
country: New Zealand
facility: Auckland Clinical Studies Ltd
city: Warszawa
country: Poland
facility: Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer
city: Omsk
country: Russian Federation
facility: BHI of Omsk region - Clinical Oncology Dispensary
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg GUZ City Clinical Oncology Dispensary
city: Badalona
country: Spain
facility: Hospital Germans Trias i Pujol
city: Cádiz
country: Spain
facility: Hospital Puerta del Mar
city: Madrid
country: Spain
facility: Fundación Jiménez Díaz
city: Sevilla
country: Spain
facility: Hospital Virgen del Rocío
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References: